BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Genetown

  New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS

  Biogen Inc. announced new 12-month data for tofersen, an investigational antisense drug for people with superoxide dismutase 1 amyotrophic lateral sclerosis.

  June 3, 2022

   · 

  12 min read
• HIV Associated Lipodystrophy Syndrome Market Insights | Global Industry Analysis [2020-2030]

  HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus -infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection.

  June 3, 2022

   · 

  7 min read
• Drug Development

  Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients

  Ionis Pharmaceuticals, Inc. partner Biogen announced results from the Phase 3 VALOR study and its open-label extension of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 amyotrophic lateral sclerosis.

  June 3, 2022

   · 

  8 min read